



Recent Advances in Drug Discovery and Evaluation for the Treatment of Affective Disorders and Schizophrenia

Guest Editors:

Dr. Jolanta Orzelska-Górka

Dr. Marta Kruk-Słomka

Dr. Ewa Kędzierska

Dr. Ewa Gibuła-Tartowska

Deadline for manuscript
submissions:

closed (20 April 2024)

Message from the Guest Editors

Mental disorders are a major public health concern. Depression and schizophrenia represent some of the most prevalent and highly comorbid psychiatric conditions. Currently, the use of antipsychotic drugs, as monotherapy or as adjuncts to antidepressants and mood-stabilizing medicines, is also common practice for mood disorders that are not necessarily associated with psychosis. Furthermore, the use of many antipsychotic drugs carries a risk of serious adverse effects that may not only significantly affect a patient's quality of life but also shorten its duration. These problems are indications of the need to search for new treatments for mental diseases that are characterized by beneficial pharmacological effects and suitable safety profile actions.

Thus, this Special Issue aims to address the pressing need for the development of new drugs to treat affective disorders and/or schizophrenia. The aim of this project is to bring together international experts to provide a comprehensive overview of this research field. Therefore, I invite you to participate with either an original article or a review focused on some aspects of the subject.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com